Piramal Pharma Expands Its Biologics Presence Through Yapan Bio Acquisition

Overview

On August 18, 2026, Piramal Pharma Limited (PPL) announced the completion of its acquisition of a 40.67% stake in Yapan Bio Private Limited, increasing its total ownership to 74%. With this acquisition, Yapan Bio transitions from an associate company to a full subsidiary, significantly enhancing PPL’s portfolio in the biologics sector, particularly in the development and manufacturing of vaccines and biologics.

The Strategic Move

Founded in Hyderabad, Yapan Bio specializes in advanced process development and GMP manufacturing services for vaccines and biologics. The integration of Yapan Bio under Piramal's umbrella is aimed at delivering a more robust set of capabilities in the complex arena of large molecule manufacturing. This not only represents a substantial investment of ₹76 crore (approximately $7.95 million USD) but also solidifies Piramal Pharma’s commitment to advancing patient-centric solutions.

Peter DeYoung, CEO of Piramal Global Pharma, emphasized that this acquisition propels their long-term growth strategy as it empowers their partners in response to the surging demand for biologics worldwide. The integration ensures that partners can navigate the complexities of biologics with greater ease, ultimately benefiting patients who require consistent access to vital therapies.

Enhancing ADCelerate™

The acquisition is particularly transformative for the ADCelerate™ platform, Piramal’s integrated service offering that streamlines the development of antibody-drug conjugates (ADCs) from research and development through to GMP manufacturing, all within a 12-month cycle. With Yapan Bio onboard, this platform is poised to deliver life-saving therapies to market more swiftly and reliably, significantly enhancing Piramal’s capabilities in the ADC landscape.

Broader Impact on the Biologics Market

Piramal Pharma Solutions (PPS), the CDMO arm of PPL, will benefit greatly from this acquisition. By embedding Yapan Bio’s expertise in large molecule applications, Piramal aims to not only strengthen its product offerings but also respond to the increasing demand for integrated contract development and manufacturing solutions. This aligns with the pharmaceutical industry’s broader trend towards consolidation and integration to better meet market needs.

Piramal has been proactive in expanding its service offerings globally, establishing a network that spans North America, Europe, and Asia. This strategic investment in Yapan Bio is expected to play a crucial role in driving growth and fostering innovation in complex drug development circles globally.

About Piramal Pharma Limited

PPL operates through its diverse business segments, including Piramal Pharma Solutions (CDMO services), Piramal Critical Care (hospital generics), and Piramal Consumer Healthcare. The recent acquisition of Yapan Bio further complements PPL's comprehensive approach to meet the unique needs of healthcare providers and the patients they serve.

As the pharmaceutical landscape continues to evolve, PPL’s focused investments signify their determination to remain at the forefront of drug development, ensuring high-quality therapies reach the people who need them most.

In summary, Piramal Pharma's acquisition of Yapan Bio not only enhances its biological capabilities but also reinforces its market position as a leader in the contract development and manufacturing segment—paving the way for more effective, faster solutions in biopharmaceuticals.